一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.3100 | 0.2200 | 40.91 | 0.2000 | | 每股净资产（元） | 8.73 | 7.81 | 11.78 | 7.52 | | 每股公积金(元) | 3.34 | 3.4 | -1.76 | 3.4 | | 每股未分配利润(元) | 3.92 | 3.08 | 27.27 | 2.71 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.52 | 1.13 | 34.51 | 1.09 | | 净利润(亿元) | 0.23 | 0.17 | 35.29 | 0.15 | | 净资产收益率(%) | 3.60 | 2.89 | 24.57 | 3.42 | 数据四舍五入，查看更多财务数据>> 前十大流通股东累计持有： 3045.75万股，累计占流通股比： 62.87%，较上期变化： -224.69万股。 | 名 ...

证券代码：839273 证券简称：一致魔芋 公告编号：2025-062 湖北一致魔芋生物科技股份有限公司 关于召开 2025 年第二次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东应选择现场投票或网络投票的一种方式，如果同一表决权出 现重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 5 月 13 日 15:00。 （一）股东会届次 本次会议为 2025 年第二次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 （三）会议召开的合法性、合规性 本次会议的议案已于 2025 年 4 月 26 日经公司第三届董事会第二十三次会议 审议通过。本次股东会的召开时间、召开方式及召集人符合《公司法》、《公司章 程》及《股东大会议事规则》等有关规定，无需其他相关部门批准或履行必要程 序。 （四）会议召开方式 2、网络投票起止时间：202 ...

本次会议程序符合《公司法》及《公司章程》的有关规定，会议决议为有效 决议。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 证券代码：839273 证券简称：一致魔芋 公告编号：2025-059 湖北一致魔芋生物科技股份有限公司 第三届监事会第二十二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 6.召开情况合法、合规、合章程性说明： 二、议案审议情况 （一）审议通过《关于公司<2025 年第一季度报告>的议案》 1.议案内容： 根据《公司法》《证券法》《北京证券交易所上市规则》等法律法规及《公司 章程》有关规定，公司已编制完成《2025 年第一季度报告》。 1.会议召开时间：2025 年 4 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2025 年 4 月 21 日以通讯方式发出 5.会议主持人：监事会主席万静女士 具体内容请详见公司于 2025 年 4 ...

证券代码：839273 证券简称：一致魔芋 公告编号：2025-058 湖北一致魔芋生物科技股份有限公司 第三届董事会第二十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2025 年 4 月 21 日以通讯方式发出 5.会议主持人：董事长吴平女士 6.会议列席人员：全体监事 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》《公司章程》《董事会议事规则》的相 关规定。 根据《公司法》《证券法》《北京证券交易所上市规则》等法律法规及《公司 章程》有关规定，公司已编制完成《2025 年第一季度报告》。 具体内容请详见公司于 2025 年 4 月 28 日在北京证券交易所信息披露平台 （https://www.bse.cn）披露的《2025 年一季度报告》（公告编号：2025-0 ...

Financial Performance - Net profit attributable to shareholders for Q1 2025 was CNY 22,701,930.67, representing a 36.95% increase year-over-year[10] - Operating revenue for Q1 2025 reached CNY 152,092,618.50, up 35.03% from the same period last year[10] - The weighted average return on equity increased to 3.60% from 2.89% year-over-year, indicating improved profitability[10] - The company's net profit for Q1 2025 reached CNY 22,343,832.68, a 34.1% increase compared to CNY 16,630,218.91 in Q1 2024[43] - Operating revenue for Q1 2025 was CNY 140,883,610.79, up 31.3% from CNY 107,239,654.12 in Q1 2024[43] - The operating profit for Q1 2025 was CNY 28,918,458.74, compared to CNY 20,313,278.87 in Q1 2024, reflecting a growth of 42.5%[43] - The total comprehensive income for Q1 2025 was CNY 22,343,832.68, compared to CNY 16,630,218.91 in Q1 2024, reflecting a growth of 34.1%[44] Cash Flow and Liquidity - The net cash flow from operating activities increased by 116.06% to CNY 74,981,115.63 due to higher sales collections[10] - Operating cash flow for Q1 2025 was 67,831,785.04 CNY, a significant increase from 24,430,326.86 CNY in Q1 2024, reflecting improved operational efficiency[48] - Cash inflow from operating activities totaled 163,141,635.69 CNY in Q1 2025, compared to 130,425,449.83 CNY in Q1 2024, reflecting a 25% increase[47] - Cash and cash equivalents increased by 69.79% to CNY 99,756,393.93, attributed to increased sales receipts during the reporting period[11] - Cash and cash equivalents at the end of Q1 2025 totaled 88,325,584.18 CNY, down from 111,335,152.57 CNY at the end of Q1 2024, indicating a liquidity contraction[48] - The net increase in cash and cash equivalents for Q1 2025 was 38,944,642.00 CNY, down from 57,124,378.49 CNY in Q1 2024, indicating a slowdown in cash generation[48] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 780,582,727.80, a decrease of 0.50% compared to the end of 2024[10] - The company's total liabilities to assets ratio decreased to 17.58% from 21.10% year-over-year, indicating improved financial stability[10] - The company's total liabilities decreased to 137,195,190.16 CNY from 165,560,862.70 CNY, a decline of approximately 17.1%[35] - The company's equity attributable to shareholders increased to 643,591,772.33 CNY from 619,148,692.83 CNY, reflecting an increase of about 3.9%[35] - Accounts receivable decreased to 65,354,113.44 CNY from 72,875,867.71 CNY, indicating a reduction of about 10.3%[33] Research and Development - Research and development expenses rose by 39.92% to CNY 5,709,516.26, reflecting the company's commitment to innovation[12] - Research and development expenses increased to CNY 4,586,700.60 in Q1 2025 from CNY 3,449,147.73 in Q1 2024, marking a rise of 32.9%[43] Shareholder Information - The total number of unrestricted shares is 48,447,400, accounting for 65.69% of the total share capital[17] - The total number of restricted shares is 25,306,600, representing 34.31% of the total share capital[18] - The largest shareholder, Wu Ping, holds 19,590,000 shares, which is 26.56% of the total shares[19] - The second-largest shareholder, Li Li, owns 10,400,000 shares, equivalent to 14.10% of the total shares[19] - The total number of shares outstanding is 73,754,000[18] - The total number of shares held by the top ten shareholders is 52,987,400, representing 71.84% of the total shares[20] Government Subsidies and Other Income - The company reported a significant increase in government subsidies, which rose by 466.82% to CNY 6,259,318.66, contributing positively to financial performance[12] - Other income increased to CNY 5,898,965.28 in Q1 2025 from CNY 821,071.06 in Q1 2024, indicating a substantial growth of 619.5%[43] Debt and Commitments - The company repaid 20,000,000.00 CNY in debt during Q1 2025, compared to no repayments in Q1 2024, reflecting a strategic focus on debt reduction[48] - The company has no major litigation or arbitration matters during the reporting period[24] - The company has no new commitments during the reporting period, maintaining previously disclosed commitments[28]

变更登记的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：839273 证券简称：一致魔芋 公告编号：2025-061 湖北一致魔芋生物科技股份有限公司 关于拟变更公司注册资本及修订《公司章程》并办理工商 公司拟实施 2024 年年度权益分派，公司目前总股本为 73,754,000 股，根据 扣除回购专户 167,982 股后的 73,586,018 股为基数，以未分配利润向全体股东每 10 股派发现金红利 5 元（含税），以资本公积向全体股东每 10 股转增 4 股（其 中以股票发行溢价所形成的资本公积每 10 股转增 4 股，无需纳税；以其他资本 公积每 10 股转增 0 股，需要纳税）。本次权益分派方案已经 2024 年年度股东大 会审议通过，方案实施完成后，预计公司总股本由 73,754,000 股增加至 103,188,407 股，预计注册资本由 73,754,000 元增加至 103,188,407 元。 三、备查文件 《湖北一致魔芋生物科技股份有限公司第三届董事会第二十三次 ...

2024 年年度权益分派实施公告 证券代码：839273 证券简称：一致魔芋 公告编号：2025-057 湖北一致魔芋生物科技股份有限公司 以公司股权登记日应分配股数 73,586,018 股为基数（应分配总股数等于股权 登记日总股本 73,754,000 股减去回购的股份 167,982 股，根据《公司法》等规定， 公司持有的本公司股份不得分配利润），向参与分配的股东每 10 股转增 4 股，（其 中以股票发行溢价形成的资本公积金每 10 股转增 4 股，不需要纳税；以其他资 本公积每 10 股转增 0 股，需要纳税），每 10 股派 5 元人民币现金。分红前本公 司总股本为 73,754,000 股，分红后总股本增至 103,188,407 股。 2、扣税说明 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 湖北一致魔芋生物科技股份有限公司 2024 年年度权益分派方案已获 2025 年 4 月 15 日召开的股东大会审议通过，本次实施分配方案距离股东大会审议通 过的时间未超过两个月。 现将权益分派 ...

Market Overview - On April 22, the total trading volume of individual stocks on the Beijing Stock Exchange reached 1.519 billion shares, with a total transaction value of 31.381 billion yuan, a decrease of 1.024 billion yuan compared to the previous trading day [2] - Among the tradable stocks, 68 stocks closed higher, accounting for 25.66% of the total tradable stocks, while 194 stocks closed lower [2] Notable Performers - The stocks with the highest closing gains included Fangda New Materials, which surged by 29.94%, and Guangdao Digital, which increased by 19.67% [2][3] - Stocks with significant declines included Dir Chemical, which fell by 7.30%, and Kangbiter, which dropped by 7.12% [2] Trading Activity - A total of 102 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Airong Software (1.226 billion yuan), Development Technology (875.194 million yuan), and Xingtou Measurement and Control (647.395 million yuan) [2] - The trading activity showed that 67 stocks had a turnover rate exceeding 10%, with 15 stocks exceeding 20% [2] Detailed Stock Performance - The top-performing stocks by closing price and turnover rate included: - Airong Software: Closing price of 61.58 yuan, up 4.67%, turnover rate of 15.58% [2] - Development Technology: Closing price of 121.88 yuan, up 3.30%, turnover rate of 23.09% [2] - Guangdao Digital: Closing price of 13.63 yuan, up 19.67%, turnover rate of 31.38% [3] Summary of Declining Stocks - Notable declining stocks included: - Dir Chemical: Closing price of 14.86 yuan, down 7.30%, turnover rate of 19.61% [3] - Kangbiter: Closing price of 24.51 yuan, down 7.12%, turnover rate of 7.90% [3] - Minshida: Closing price of 47.90 yuan, down 6.83%, turnover rate of 19.60% [2]

Group 1 - In the past month (from March 23 to April 22), 18 companies listed on the Beijing Stock Exchange (BSE) were investigated by institutions, with Minshida being the most notable, receiving attention from 139 institutions [1] - The types of institutions conducting the research included 17 brokerages, 14 funds, 13 private equity firms, 10 insurance companies, and 2 overseas institutions [1] - The companies that received the most institutional attention were Minshida, Yizhi Moyu, Litong Technology, and Audiwei, with 139, 137, 77, and 65 institutions participating in their investigations, respectively [1] Group 2 - The average stock price of the companies investigated by institutions increased by 16.14% over the past month, with notable increases from Yizhi Moyu (154.56%), Minshida (74.82%), and Jikang Instruments (28.51%) [2] - The average daily turnover rate for the investigated companies was 7.51%, with the highest rates recorded for Zhongke Meiling (17.38%), Minshida (16.18%), and Guohang Yuanyang (15.31%) [2] - As of April 22, the average market capitalization of all companies on the BSE was 2.89 billion yuan, while the average market capitalization of the investigated companies was 3.30 billion yuan, with Hualing Co., Minshida, and Fujida leading in market value [2]

Group 1: Company Development Focus for 2025 - Accelerate the construction of fundraising projects [4] - Increase R&D investment in konjac powder applications and expand its market share [4] - Focus on expanding markets for konjac products such as konjac素毛肚, konjac tea ingredients, and dietary fiber [4] - Deepen cooperation with key clients to enhance composite colloid technology advantages [4] - Promote the steady growth of the self-owned brand "Magic Brother" in tourism channels and online platforms [4] Group 2: Supply and Market Insights - High enthusiasm for konjac planting among farmers, with expected growth in planting area [5] - Supply-side growth is limited due to specific growing conditions and climate impact [5] - The konjac industry will explore markets focusing on health, functionality, environmental sustainability, and globalization [6] Group 3: Health Benefits and Product Information - Konjac is rich in soluble dietary fiber, beneficial for lowering blood lipids, regulating sugar metabolism, and improving gut function [7] - The shelf life of konjac powder is 18 months, while processed konjac gel can last up to 24 months [8] Group 4: Financial and Supply Chain Management - The company plans to gradually transmit cost pressures through a "cost-plus pricing" strategy to maintain stable gross margins [9] - Unique supply chain management through equipment leasing, technical support, and capacity locking with reputable cooperatives [10]